SBP solbec pharmaceuticals limited

genentech up $11 billion, page-4

  1. 5,995 Posts.
    lightbulb Created with Sketch. 162
    DNAs(Genentech) Avastin was approved about a year ago for use on colon cancer . The $11B jump was just for the new approval for Avastin on NSCLC . Indications are that Coramsine will raise the bar considerably higher again . It is my guess that Solbec will probably concentrate on orphan drug uses , such as melonoma and mesothelioma with the prospect of accellerated approval before trials are completed .
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.